Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Cedilla Therapeutics is raising $60,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Alexandra Glucksmann played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cedilla Therapeutics

Cedilla is harnessing intrinsic protein stability mechanisms to broaden the reach of small molecule therapeutics. We work on cancer and other diseases caused by protein dysregulation. We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stabilize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.

To learn more about Cedilla Therapeutics, visit http://www.cedillatx.com/

Contact:
Alexandra Glucksmann, President and Chief Executive Officer
https://www.linkedin.com/in/alexandra-sandra-glucksmann-417a432/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved